Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AML
June 11th 2023Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.
Read More
Dr. Levis on Gilteritinib in Relapsed/Refractory FLT3-Mutated AML
September 6th 2019Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.
Read More